Alkermes
forward looking statements and non financial information certain statements set forth in this presentation constitute forward looking statements within the meaning of the private securities litigation reform act of as amended including but not limited to statements concerning the company expectations with respect to its current and future financial and operating performance business plans or prospects including revenue growth from its current commercial product portfolio and the addition of potential new revenue streams and the company plans and ability to manage for growth and profitability including achievement of its stated profitability targets through revenue growth expense management and optimization of its cost structure and exploration of strategic opportunities the potential therapeutic and commercial value of the company marketed products and development candidates expectations regarding patient life for the company products expectations regarding the effectiveness and cost efficiency of the company research and development strategy and the potential of the company capabilities including its molecule design and engineering capabilities plans and expectations for development activities relating to the company products and development candidates including i for alfa plans to initiate studies in mucosal melanoma and platinum resistant ovarian cancer to support potential registration further explore the potential synergistic benefits of to existing cancer treatments and pursue strategic collaborations for plans to initiate phase first in human trials and for the company other early stage programs including its program its engineered platform including and and its inhibitor platform plans to conduct proof of concept studies and or other enabling activities advance towards characterization and nomination of lead candidates and identify and initial potential indications the company expectations relating to regulatory activities and interactions including the food and drug administration target action date for the company new drug application for and plans to advance discussions on registration plans for expectations concerning commercial activities relating to the company products and product candidates including preparations for the potential commercial launch of the company cautions that forward looking statements are inherently uncertain these risks assumptions and uncertainties include among the impacts of the ongoing covid pandemic and continued efforts to mitigate its spread on the company business results of operations or financial condition the unfavorable outcome of litigation including so called paragraph litigation and other patent litigation related to any of the company products which may lead to competition from generic drug manufacturers the may not agree with the company regulatory approval strategies or components of the company including clinical trial designs conduct and methodologies manufacturing processes and facilities or the adequacy of the data or other information included in the company regulatory submissions to support the requirements for approval and may make adverse decisions regarding the company products including with respect to the for the company development activities may not be completed on time or at all the results of the company development activities may not be positive or predictive of real world results and preliminary data from ongoing studies may not be predictive of future or final data from such studies results of future studies or real world results the company and its licensees may not be able to successfully commercialize their products or support growth of revenue from such products there may be a reduction in payment rate or reimbursement for the company products or an increase in the company financial obligations to governmental payers the company products may prove difficult to manufacture be precluded from commercialization by the proprietary rights of third parties or have unintended side effects adverse reactions or incidents of misuse and those risks assumptions and uncertainties described under the heading risk factors in the company annual report on form for the year ended and in subsequent filings made by the company with the securities and exchange commission sec which are available on the sec at sec and on the company at alkermes in the investors sec filings section existing and prospective investors are cautioned not to place undue reliance on these forward looking statements which speak only as of the date hereof except as required by law the company disclaims any intention or responsibility for updating or revising any forward looking statements contained in this presentation non financial measures this presentation includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the including non net income and these non measures are not based on any standardized methodology prescribed by and are not necessarily comparable to similar measures presented by other companies reconciliations of non financial measures to the most directly comparable financial measures to the extent reasonably determinable can be found on the investors page of the company note regarding the company and its affiliates are the owners of various federal registrations and other including and is a registered of biogen used by alkermes under license any other referred to in this presentation are the property of their respective owners appearances of such other herein should not be construed as any indicator that their respective owners will not assert their rights thereto | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
2 of 144
Similar slides by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Related slides by other companies
Results
May 2017
Results
January 2021
Results
May 2022
Investor Presentation
June 2022
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io